Léčba pacientů přípravkem buněčné terapie axikabtagen ciloleucel
| Title in English | Cellular therapy with axicabtagene ciloleucel |
|---|---|
| Authors | |
| Year of publication | 2021 |
| Type | Article in Periodical |
| Magazine / Source | Klinická farmakologie a farmacie |
| Citation | |
| Keywords | hematooncology, lymphoma, cellular therapy, chimeric antigen receptor (CAR) T-cells, axicabtagene ciloleucel |
| Description | Patients with relapsed/refractory non-Hodgkin B-cell lymphomas suffer from a very poor survival. Chimeric antigen receptor T-cells (CAR-T) offer an attractive treatment approach using autologous genetically modified immune-effector cells. Main advantages include good treatment response, short-term and predictable toxicity profile, and prolonged survival. This review summarizes clinical trials with axicabtagene ciloleucel (axi-cel, Yescarta), published results, and real-world experience including first Czech data. |